title: Antivascular endothelial growth factor as an approach for macular edema.
abstract: Macular edema is an abnormal thickening of the macula associated with the accumulation of excess fluid in the extracellular space of the neurosensory retina. The following chapter looks at the basic pathomechanisms of macular edema as well as major pathologic conditions leading to it: special focus is on diabetic retinopathy, retinal venous occlusions and a number of inflammatory disorders. Currently available data on up-to-date pharmacologic treatment options such as steroids and anti-VEGF compounds is presented and discussed.
authors: P M
authors: PM
authors: Buchholz
authors: A P
authors: AP
authors: Buchholz
authors: A J
authors: AJ
authors: Augustin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002386:Cataract / Q000150:complications; D002387:Cataract Extraction / Q000009:adverse effects; D003930:Diabetic Retinopathy / Q000150:complications; D005451:Fluorescein Angiography; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications; D013256:Steroids / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D013256:Steroids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab